Altimmune (ALT) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $7.8 million.
- Altimmune's Accumulated Expenses rose 395.74% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 395.74%. This contributed to the annual value of $10.3 million for FY2024, which is 182.67% up from last year.
- Latest data reveals that Altimmune reported Accumulated Expenses of $7.8 million as of Q3 2025, which was up 395.74% from $8.4 million recorded in Q2 2025.
- Altimmune's 5-year Accumulated Expenses high stood at $19.1 million for Q3 2021, and its period low was $7.4 million during Q2 2023.
- Moreover, its 5-year median value for Accumulated Expenses was $9.7 million (2023), whereas its average is $10.3 million.
- In the last 5 years, Altimmune's Accumulated Expenses soared by 25286.03% in 2021 and then plummeted by 3838.58% in 2023.
- Over the past 5 years, Altimmune's Accumulated Expenses (Quarter) stood at $10.2 million in 2021, then grew by 20.67% to $12.2 million in 2022, then decreased by 17.77% to $10.1 million in 2023, then grew by 1.83% to $10.3 million in 2024, then decreased by 23.93% to $7.8 million in 2025.
- Its Accumulated Expenses stands at $7.8 million for Q3 2025, versus $8.4 million for Q2 2025 and $8.7 million for Q1 2025.